E-cigarettes Show Lower Cell Toxicity Than Traditional Cigarettes

Nov.18.2022
E-cigarettes Show Lower Cell Toxicity Than Traditional Cigarettes
The study found that e-cigarettes have less impact on cells than traditional cigarettes, using extracellular vesicle proteomics for analysis.

On November 5th, a research team led by Associate Researcher Yu Suhong from Fuzhou University published a paper in the authoritative global toxicology journal, "Toxicology in Vitro," which found that the impact of electronic cigarettes on cells is significantly lower than that of traditional cigarettes.


The study used exosome proteomics for the first time to compare the effects of electronic cigarettes and traditional cigarettes on human bronchial epithelial cells. Exosomes are small membrane vesicles containing complex RNA and proteins, which can be used as biomarkers for early diagnosis and prognosis evaluation of diseases such as cancer.


Research data shows that cigarette tar leads to more differences in protein expression of extracellular vesicles within cells, and these are significantly enriched in cancer signaling pathways. Meanwhile, differences caused by e-cigarettes are less pronounced. Toxicology studies have also found that cigarette tar significantly inhibits cell activity, while e-cigarette tar did not produce similar negative effects, indicating that the cellular toxicity of e-cigarettes is relatively low.


The paper was published in the toxicology SCI journal, "In Vivo Toxicology.


In recent years, several studies have found that electronic cigarettes may be a form of harm reduction product.


In 2021, the Pennsylvania State University College of Medicine published a paper in Cancer stating that e-cigarettes could be effective tools for quitting smoking and also decrease the production of carcinogens in smokers' lungs. In 2022, an editorial in Nature suggested that for patients with gum health concerns, e-cigarettes may be a safer nicotine substitute and could reduce the risk of oral cancer.


According to Associate Researcher Yu Suhong, this study is the first to systematically analyze the safety of cigarettes and e-cigarettes starting from extracellular vesicles, filling a gap in the relevant field.


According to research findings, electronic cigarettes are less harmful than traditional cigarettes and may be a reduced-harm product," said Yu Suhong. However, electronic cigarettes are not entirely safe and should not be used by non-smokers.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

New York’s Lawsuit Against Puff Bar and Other Flavored Vape Companies Survives Key Court Challenge
New York’s Lawsuit Against Puff Bar and Other Flavored Vape Companies Survives Key Court Challenge
According to Law360, a federal judge ruled that makers and distributors of flavored vape brands such as Puff Bar cannot escape New York’s lawsuit seeking to hold them responsible for the youth vaping epidemic. The court found that the state had adequately alleged the companies misrepresented how safe vaping is.
Apr.07 by 2FIRSTS.ai
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Tobacco Center Plans Faster Review Process for Certain Supplemental PMTAs
FDA Center for Tobacco Products Acting Director Bret Koplow issued a statement on May 7 outlining new steps to accelerate tobacco product premarket application review. The statement said CTP reduced the backlog of applications by approximately 70% in 2025 and that there is no longer a queue for PMTAs pending acceptance review.
May.09 by 2FIRSTS.ai
Australia Plans Tougher Penalties for Illicit Tobacco and Vape Crime
Australia Plans Tougher Penalties for Illicit Tobacco and Vape Crime
The Australian government is preparing a new crackdown on the illicit tobacco market, including stronger penalties, expanded police surveillance powers and tougher asset seizure measures.
Mar.19 by 2FIRSTS.ai
FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
The U.S. Food and Drug Administration (FDA) announced on May 5, 2026 that it authorized the marketing of four Glas electronic nicotine delivery system (ENDS) products through the premarket tobacco product application (PMTA) pathway. The authorized products are Classic Menthol, Fresh Menthol, Gold and Sapphire pods, each containing 50mg/ml, or 5%, tobacco-derived nicotine.
May.06 by 2FIRSTS.ai
New Movement Emerges on EU Tobacco Excise Directive as Cyprus Tables Compromise Draft
New Movement Emerges on EU Tobacco Excise Directive as Cyprus Tables Compromise Draft
The long-stalled debate over the European Union’s Tobacco Excise Directive may be moving forward, with Cyprus, as holder of the EU Council presidency, putting forward a compromise draft. The reported proposal includes lowering the minimum excise duty requirement and granting a transitional period, with the aim of reaching political agreement by June 2026. The revision also covers e-cigarettes, heated tobacco, nicotine pouches and stronger controls on raw tobacco.
Apr.21 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13